Vivesto AB announced the appointment of Dr. Daniel Tesfa as Chief Medical Officer (CMO), who will be responsible for leading the clinical development of all Vivesto's oncology programmes in concert with CSO, Dr. Reinhard Koenig, responsible for all pre-clinical activities. Dr. Tesfa, who will join Vivesto no later than 1 July, will report to CEO Francois Martelet and will also join Vivesto's Management team. Dr. Tesfa brings extensive experience in clinical development and precision oncology over 20 years.

Most recently, from 2020, he served as Medical Director, Clinical and Translation Science Hematology at listed Swedish biopharmaceutical company SOBI (Swedish Orphan Biovitrum AB), where he led clinical development. Prior to his time at SOBI, from 2018 until 2020, Dr. Tesfa worked as Head of Oncology and Hematology at Bayer, Scandinavia, where he was a Medical Advisor and manager for the medical team.